Ocuphire Pharma Results Presentation Deck

RM Pupil Diameter (mm) 17 9 8 LO 4 3 Secondary Endpoint: Mean Pupil Diameter Over Time by Eye Color Nyxol Reduced Pupil Diameter More Rapidly in Both and Light Dark Irides p<0.0001 I Max pupil dilation, Treatment Mydriatic -1 0 0.5 TH p<0.0001 Light Irides T I p<0.0001 -Nyxol (n=45) I TH p<0.0001 +4 p<0.0001 MIRA-2 Phase 3 Trial Study Eye, mITT Population Placebo (n=45) 1 1.5 2 3 4 Time Post-Treatment with Nyxol/Placebo (Hours) I p<0.0001 6 Pupil Diameter (mm) 9 8 4 3 Max pupil dilation, Treatment Mydriatic -1 0 +4 p<0.0001 Dark Irides p<0.0001 p<0.0001 -Nyxol (n=49) Source MIRA-2 TLR table # 14.2.1.5. Standard Error bars are shown. Data includes all three mydriatics (Phenylephrine, Tropicamide, Paremyd) T p<0.0001 I Placebo (n=46) I p<0.0001 0.5 1 1.5 2 3 4 Time Post-Treatment with Nyxol/Placebo (Hours) HA I p<0.0001 6 Ocuphire PHARMA

View entire presentation